by Optimi Communications | Jun 29, 2022 | In The Media
Optimi CEO, Bill Ciprick, recently sat down with Investing News Network’s (INN) Stuart McNish to talk about a host of things all psychedelics and Optimi’s plan to commercialize and supply the next generation of natural psilocybin and synthetic psychedelic... by Optimi Communications | Jun 28, 2022 | Corporate News
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for... by Optimi Communications | Jun 22, 2022 | In The Media
Optimi Health has submitted a request to Canadian authorities that would allow the company to produce MDMA and other psychedelics at its facility in British Columbia. BY A.J. HERRINGTON A Canadian company that produces functional mushroom formulations for health and... by Optimi Communications | Jun 20, 2022 | Corporate News
Company to maximize world-class EU-GMP operations, potentially opening future revenue-generating opportunities VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”) or the (“Company”), a homegrown, Canadian company producing... by Optimi Communications | Jun 8, 2022 | Corporate News
Strategic partnership will focus on improving regulatory outcomes in therapist training and safe supply of psilocybin VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing...
